Humanigen is taking action on the novel coronavirus outbreak. Refer to this page for the latest educational resources and information on lenzilumab as a therapeutic for cytokine storm resulting from COVID-19 infection.

Follow us on Twitter

Learn how Lenzilumab may reduce serious or fatal outcomes in COVID-19 patients

Captions available (enable using video controls)
Available languages: English, Spanish (Español), Mandarin (國語), Cantonese (廣東話), Korean (한국어, 韓國語), French (Français), German (Deutsch), Italian (Italiano), Portuguese (Português)

Resources from Humanigen

First Patient Dosed in FDA-Approved Phase III Lenzilumab Study for COVID-19

Read the Full Press Release

Humanigen COVID-19 Presentation

PDF (2.4 MB)

  • Twitter

©2020 Humanigen, Inc.  All rights reserved